Analysts See $-0.32 EPS for Aldeyra Therapeutics, Inc. (ALDX)

March 14, 2018 - By Nellie Frank

 Analysts See $ 0.32 EPS for Aldeyra Therapeutics, Inc. (ALDX)
Investors sentiment increased to 3.13 in Q3 2017. Its up 1.46, from 1.67 in 2017Q2. It is positive, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 5 reduced holdings. 11 funds opened positions while 14 raised stakes. 18.26 million shares or 145.50% more from 7.44 million shares in 2017Q2 were reported.
3,183 were reported by Tower Rech Limited Company (Trc). Adage Capital Ptnrs Grp Inc Limited Liability, Massachusetts-based fund reported 750,000 shares. 85,200 were accumulated by Renaissance Technology Lc. Prelude Cap Limited Liability Corp accumulated 1,364 shares. Sphera Funds Mgmt Ltd reported 1.07% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Millennium Ltd Company accumulated 545,085 shares. Blackrock accumulated 37,667 shares. Royal Natl Bank Of Canada reported 9 shares. Ardsley Advisory Prns invested in 39,552 shares or 0.04% of the stock. Deutsche Comml Bank Ag has invested 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Barclays Plc reported 3,400 shares. Woodstock Corporation holds 0.07% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 48,393 shares. Drw Secs Limited Com accumulated 0.03% or 12,000 shares. Fmr Lc owns 1.61 million shares for 0% of their portfolio. Hikari Pwr reported 107,858 shares.

Since September 19, 2017, it had 1 buy, and 0 sales for $1.45 million activity.

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.32 EPS on March, 29.They anticipate $0.04 EPS change or 11.11 % from last quarter’s $-0.36 EPS. After having $-0.32 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see 0.00 % EPS growth. It closed at $8.85 lastly. It is down 18.94% since March 15, 2017 and is downtrending. It has underperformed by 35.64% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. Cowen & Co initiated Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on Tuesday, September 8 with “Outperform” rating. Cowen & Co maintained it with “Buy” rating and $900 target in Wednesday, August 9 report. Cantor Fitzgerald maintained Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on Thursday, November 9 with “Buy” rating. Stifel Nicolaus initiated the shares of ALDX in report on Friday, July 1 with “Buy” rating. The firm earned “Buy” rating on Wednesday, September 13 by Canaccord Genuity. H.C. Wainwright initiated the shares of ALDX in report on Monday, September 26 with “Buy” rating. Cowen & Co maintained Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on Thursday, September 14 with “Buy” rating. The rating was maintained by H.C. Wainwright on Thursday, June 15 with “Buy”. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, October 24. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, June 14.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $169.19 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More notable recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: which released: “A Second Chance To Get In On Aldeyra Therapeutics” on September 19, 2017, also with their article: “Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye …” published on February 21, 2018, published: “Aldeyra Therapeutics’ stock soars after positive results of dry eye disease …” on September 12, 2017. More interesting news about Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) were released by: and their article: “Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy” published on January 27, 2018 as well as‘s news article titled: “Aldeyra Therapeutics’ (ALDX) CEO Todd Brady on Q3 2017 Results – Earnings Call …” with publication date: November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.